Evidence map›Paper›PMID 42223819›Full record

ArticleRadiological physics and technology2026

Comparison of platinum and gold fiducial markers for prostate radiotherapy: a phantom study.

Noriyuki Mihashi, Ryoichi Hinoto, Takatsugu Kawase, Nobuhiro Tsukamoto

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Radiological physics and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Noriyuki MihashiDepartment of Radiology, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama, 336-8522, Japan. noriyuki.384@gmail.com.
Ryoichi HinotoDepartment of Radiation Oncology, Saitama Red Cross Hospital, Saitama, Japan.ORCID http://orcid.org/0009-0002-1746-5114
Takatsugu KawaseDepartment of Radiation Oncology, Saitama City Hospital, Saitama, Japan.
Nobuhiro TsukamotoDepartment of Radiation Oncology, Saitama City Hospital, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gold fiducial markers (GMs) are widely used in prostate radiotherapy; however, their magnetic susceptibility can reduce visibility on T2-weighted (T2w) MRI and may compromise CT-MRI registration. Using coil-shaped platinum fiducial markers (PMs) and GMs (5 mm in length; diameters 0.35-0.75 mm), we acquired 3 T T2w fast spin-echo MRI in an agar phantom and CT/cone-beam CT (CBCT) in a water-equivalent phantom under clinical settings. MRI visibility was quantified using the signal void area (SVA) and region-of-interest [ROI] value contrast (RVC), and CT/CBCT artifacts were quantified using an artifact index (AI). Additionally, to reflect clinical use, we evaluated CT-referenced registration estimation errors after automatic CT-MRI registration using a phantom containing a registration target. Registration errors were comparable at 0.35 mm, but were significantly smaller for PMs at 0.50 mm and 0.75 mm (p < 0.01). PMs may enable accurate T2w-based CT-MRI registration without increasing CT/CBCT artifacts.

Indexed as

Fiducial MarkersGoldPhantoms, ImagingPlatinumProstatic NeoplasmsArtifactsCone-Beam Computed TomographyHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleGoldPlatinumCT-MRI registrationMagnetic resonance imagingPlatinum markerSignal voidTreatment planning

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.